Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 16;134(2):e177160.
doi: 10.1172/JCI177160.

CAR T cells for hematological malignancies

Barbara Savoldo  1   2 , Natalie Grover  1   3 , Gianpietro Dotti  1   4
Affiliations

CAR T cells for hematological malignancies

Barbara Savoldo et al. J Clin Invest. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: BS acted as a consultant of Tessa Therapeutics; NG served on advisory board for Kite, BMS, Novartis, SeaGen, ADC Therapeutics, Genentech, Janssen, and Caribou Biosciences; GD acted as a consultant of Bellicum Pharmaceutical and Tessa Therapeutics, serves as a consultant for Catamaran, and has pending patents in the field of CAR T cells.

Figures

Figure 1
Figure 1. Simultaneous-infusion of distinct CAR-T cell products in the same patient reveals whether specific motifs support CAR-T cell expansion and function in patients with hematological malignancies.
Peripheral blood was collected from patients with hematological malignancy, such as CD19+ NHL, and used as the source for T cells in the generation of two CAR-T cell products. Transduction of activated T cells was performed using two distinct vectors encoding the first generation and second-generation CAR.CD19, and CAR-T cells were expanded in parallel. The two CAR-T cells products were then co-infused in the patient, and blood and tumor samples were collected to detect each product. PCR can be used as an assay to monitor the kinetics of each product in patients. CAR-T cells encoding the CD28 signaling motif showed superior expansion and persistence in patients with CD19+ NHL (13).
See this image and copyright information in PMC

References

    1. Heslop HE, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–935. doi: 10.1182/blood-2009-08-239186. - DOI - PMC - PubMed
    1. Eshhar Z, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–724. doi: 10.1073/pnas.90.2.720. - DOI - PMC - PubMed
    1. Scholler J, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4(132):132ra53. doi: 10.1126/scitranslmed.3003761. - DOI - PMC - PubMed
    1. Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518. doi: 10.1056/NEJMoa1215134. - DOI - PMC - PubMed
    1. Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38. doi: 10.1126/scitranslmed.3005930. - DOI - PMC - PubMed

MeSH terms

Substances